URTY
Get informed when a big investor buys or sells
+ Follow| Market cap | $37.19 Billion |
|---|---|
| Enterprise Value | $37.01 Billion |
| Dividend Yield | $0.63 (0.77%) |
| Earnings per Share | $- |
| Beta | 3.83 |
| Outstanding Shares | - |
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2834.16 |
| Enterprise Value to EBIT | -492.37 |
| Enterprise Value to Net Income | -525 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9148▲ 44.63% |
|---|---|
| Total Calls | 223,100▼ 30.54% |
| Total Puts | 204,100▲ 35.61% |
Holdings and activity of institutional investors.
| Ownership % | 12.47%▼ 4.68% |
|---|---|
| Total Invested | $26.97M▼ 29.02% |
| Investors Holding | 40▼ 5.00% |
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...